International Comparisons of Economic Burden of EndStage Renal Disease to the National Healthcare Systems
- Author:
Ismail H
- Collective Name:Abdul Manaf MR, Abdul Gafor AH , Mohamad Zaher ZM , Nur Ibrahim AI
- Publication Type:Review
- Keywords:
chronic kidney disease, end stage renal disease, dialysis, renal transplantation, national health expenditure
- From:
The International Medical Journal Malaysia
2019;18(3):188-196
- CountryMalaysia
- Language:English
-
Abstract:
The global prevalence of chronic kidney disease (CKD) is between 11 to 13%. Renal replacement therapies
(RRT) – which include dialysis and renal transplantation – consume a significant portion of a country’s health
resources even though only 0.1% of all CKD patients are at stage 5, also known as end-stage renal disease
(ESRD). The aim of this review was to compare the magnitude of the economic burden of ESRD on national
healthcare systems of selected countries with high prevalence of ESRD including Malaysia. The quantity of
interest in this review were total ESRD expenditures and its proportions to the national health systems'
expenditure. It was identified that total ESRD expenditure contributes between 0.91% to 7.1% of national
health system expenditure in countries selected for this review. In Malaysia, the public sector - through its
various agencies at the federal and state levels, accounted for almost 70% of dialysis funding; the remaining
30% came from the private sector and out-of-pocket payments. The ESRD expenditures in Malaysia
constitutes 4.2% of total health expenditure by the public sector, relatively high compared to other
countries. This review will summarise findings of the currently available economic evaluations of RRT in
Malaysia. Based on available evidence, estimated weighted cost of treating ESRD patient in Malaysia is
MYR39,346 per patient per year (USD26,648, PPP 2016).
- Full text:180324.pdf
